Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients

Background Many immune checkpoint inhibitors (ICIs) have been approved in China to treat non‐small cell lung cancer (NSCLC). However, in the long term, less than 20% of patients benefit from ICIs. To maximize the benefit for NSCLC patients, it is necessary to guide the choice of immunotherapy throug...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Peng Song, Dongliang Yang, Hanping Wang, Xiaoxia Cui, Xiaoyan Si, Xiaotong Zhang, Li Zhang
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2020-06-01
Serie:	Thoracic Cancer
Soggetti:	Β‐diversity intestinal flora non‐small cell lung cancer programmed cell death 1 (PD‐1) programmed cell death 1 ligand(PD‐L1)
Accesso online:	https://doi.org/10.1111/1759-7714.13442
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!